RxDoctor Payments Data

Anthony Cox, PA

Physician Assistant · Lincoln, NENPI 1467593384

Payments from drug & device makers

$3,054in general payments, 2019–2025

Across 159 payments — averaging $19.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Astellas Pharma US Inc$839
  • Novo Nordisk$222
  • GSK$121
  • Pfizer$120
  • Kowa Pharmaceuticals America, Inc.$59
  • plus $630 from 23 others

What the payments were for

  • Food & beverage$2,86994%
  • Education$1856%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,054 in reported general payments places this provider in the 85th percentile of 1,127 physician assistant providers in Nebraska.

See all physician assistant providers in Nebraska

Medicare billing

Part B allowed, 2024
$5,913
Medicare patients
106
Services billed
299

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin100$119,437
OzempicSemaglutide116$117,436
FarxigaDapagliflozin Propanediol71$56,272
XareltoRivaroxaban54$51,078
TradjentaLinagliptin51$48,917
EliquisApixaban50$34,445
RybelsusSemaglutide11$30,743
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$30,505
VascepaIcosapent Ethyl56$23,635
JanuviaSitagliptin Phosphate19$21,113
MyrbetriqMirabegron19$10,857
Tresiba Flextouch U-100Insulin Degludec13$9,423
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$9,345
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog20$8,393
Humalog Kwikpen U-100Insulin Lispro30$7,179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$222$148,178127 claims
Johnson & JohnsonXarelto$44$51,07854 claims
PfizerEliquis, Premarin$120$36,73761 claims
GSKTrelegy Ellipta$121$30,50538 claims
MerckJanuvia$28$21,11319 claims
Astellas Pharma US IncMyrbetriq$839$10,85719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,127 physician assistant providers in Nebraska.

Other physician assistant in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →